13 Sep2021

SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform

Written by 2020HCP.com. Posted in News

IND filing for Celiac Disease Anticipated in Third Quarter 2022

Clinical Translation Supported by Existing Red Blood Cell-Based Manufacturing Capabilities and Preclinical Models Demonstrating Treg Mediated Tolerance

WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the first clinical translation of the company’s Tolerizing Antigen Carrier (TAC) platform in autoimmune diseases will be for celiac disease, a chronic autoimmune disorder that afflicts millions of patients and has no approved drug treatment. The company anticipates an IND filing in the third quarter of 2022. In preclinical models, SQZ™ TACs have demonstrated the ability to induce multi-mechanism antigen-specific tolerance relevant to many immune mediated disorders. The company’s celiac disease program may support expansion into additional autoimmune diseases.

07 Sep2021

Verseau Therapeutics Appoints Karen Tubridy as Chief Development Officer

Written by 2020HCP.com. Posted in News

BEDFORD Mass. – September 7, 2021 – Verseau Therapeutics, Inc. today announced the appointment of
Karen Tubridy, Pharm.D. as Chief Development Officer. Karen brings over 25 years of drug development
experience within the biopharmaceutical industry. As CDO, Karen will play a leadership role in
advancing Verseau’s pipeline of first-in-class monoclonal antibodies that are directed at repolarizing
macrophages to enable the immune system to mount a potent attack on cancer.

28 Jul2021

XRHealth Receives Patent to Measure Neck and Shoulder Protraction and Retraction Motions with AR/VR Technology that Are Often Needed for Rehabilitation

Written by 2020HCP.com. Posted in News

BOSTON, July 28, 2021 /PRNewswire/ — XRHealth, the leader in extended reality and therapeutic applications, announces today that they received a patent to measure neck and shoulder protraction and retraction motions with AR/VR technology that are often practiced in occupational and physical therapy rehabilitation. XRHealth originated the method of measurement that is based on technology inherent in AR/VR, which previously had no other way to measure or guide those specific motions. The new technology will provide data for physicians to measure initial agility of patients and compare that with the outcomes after treatment, to have clearly defined results.

27 Jul2021

XRHealth and Reducept Offer Patients Virtual Reality Therapy for Pain Management

Written by 2020HCP.com. Posted in News

BOSTON, July 26, 2021 /PRNewswire/ — XRHealth, the leader in extended reality and therapeutic applications, announced today that they are working with Reducept to expand their offering to patients for virtual reality therapy for pain management. The virtual reality technology provides exercises that train people suffering from chronic pain on how to gain control over pain, potentially reducing the need for medication.

02 Jul2021

SQZ Biotechnologies Strengthens Board with Global Commercial and Clinical Development Experience

Written by 2020HCP.com. Posted in News

Bernard Coulie, M.D., Ph.D. and Patrick Vink, M.D. Join Board of Directors

WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the appointments of Bernard Coulie, M.D., Ph.D., and Patrick Vink, M.D., to its board of directors, adding global commercial and clinical development expertise.

Latest News